Journal Information
Issue
Vol. 42. Issue S1.
Pages 1-78 (October 2020)
XIth Eurasian Hematology Oncology
Hematol Transfus Cell Ther. 2020;42 Supl 1:i
Open access
POSTER PRESENTATIONS
Hematol Transfus Cell Ther. 2020;42 Supl 1:3188
Open access
SPEAKER PRESENTATIONS
Hematol Transfus Cell Ther. 2020;42 Supl 1:3186
Open access
ORAL PRESENTATIONS
Hematol Transfus Cell Ther. 2020;42 Supl 1:3187
Open access
Welcome Address
Hematol Transfus Cell Ther. 2020;42 Supl 1:ii-iv
Open access
Speaker Biographies
Hematol Transfus Cell Ther. 2020;42 Supl 1:v-xv
Open access
Speaker presentations
TIM-3/Gal-9 signaling is the molecular target for human myeloid leukemia treatment
Koichi Akashi
Hematol Transfus Cell Ther. 2020;42 Supl 1:1
Open access
Development of novel therapies in MDS
Kinuko Mitani
Hematol Transfus Cell Ther. 2020;42 Supl 1:1
Open access
Risk scores and risk factors in CML, are they helpful?
Tomasz Sacha
Hematol Transfus Cell Ther. 2020;42 Supl 1:2
Open access
Minimal residual disease detection in multiple myeloma: methods and prognostic significance
Evangelos Terpos
Hematol Transfus Cell Ther. 2020;42 Supl 1:2
Open access
Treatment of relapsed, refractory multiple myeloma: focus on new drugs
Angelo Maiolino
Hematol Transfus Cell Ther. 2020;42 Supl 1:2-3
Open access
Current therapy for indolent lymphomas
Guilherme Duffles Amarante, Marcia Torresan Delamain, Carmino Antonio De Souza
Hematol Transfus Cell Ther. 2020;42 Supl 1:3-5
Open access
Bone marrow failure
Rodrigo T. Calado
Hematol Transfus Cell Ther. 2020;42 Supl 1:5
Open access
Immunocompromised patients: prevention, diagnosis and therapy of infection
Marcio Nucci
Hematol Transfus Cell Ther. 2020;42 Supl 1:5
Open access
Paroxysmal nocturnal hemoglobinuria pnh
Hanan Hamed
Hematol Transfus Cell Ther. 2020;42 Supl 1:5-6
Open access
Access to cancer medicines and targeted therapies in developing countries
Zeba Aziz
Hematol Transfus Cell Ther. 2020;42 Supl 1:6
Open access
Ph-positive and ph-like all: how can we further improve?
Robin Foà
Hematol Transfus Cell Ther. 2020;42 Supl 1:6-7
Open access
CAR T-cell in children all
Francesco Saglio
Hematol Transfus Cell Ther. 2020;42 Supl 1:7
Open access
Update on chimeric antigen receptor – T cells (CAR-T) CD19 therapy: the Sheba experience
Arnon Nagler
Hematol Transfus Cell Ther. 2020;42 Supl 1:7-8
Open access
Treatment of sickle cell crises
Salam Alkindi
Hematol Transfus Cell Ther. 2020;42 Supl 1:8
Open access
Secondary acute leukemia evolving from myeloproliferative neoplasm (MPN)
Tariq Mughal
Hematol Transfus Cell Ther. 2020;42 Supl 1:8-9
Open access
The new European leukemianet recommendations for treating CML
Rüdiger Hehlmann
Hematol Transfus Cell Ther. 2020;42 Supl 1:9
Open access
Ex vivo activation of pleural T cells in pleural malignancies
Vera S. Donnenberg, James D. Luketich, Albert D. Donnenberg
Hematol Transfus Cell Ther. 2020;42 Supl 1:9-10
Open access
Are there really cancer stem cells and how do they operate?
Robert Gale
Hematol Transfus Cell Ther. 2020;42 Supl 1:10
Open access
Challenges in treating solid tumors in developing countries
Adnan Abdul Jabbar
Hematol Transfus Cell Ther. 2020;42 Supl 1:10-1
Open access
Lymphoblastyc lymphoma/leukemia: a single center experience
Alina Antipova, Olga Baranova
Hematol Transfus Cell Ther. 2020;42 Supl 1:11
Open access
Relapsed and refractory classical Hodgkin lymphoma immunotherapy
Kirill Lepik
Hematol Transfus Cell Ther. 2020;42 Supl 1:11-2
Open access
Literature review: the year in apheresis – what is new?
Joseph Schwartz
Hematol Transfus Cell Ther. 2020;42 Supl 1:12
Open access
The ASFA therapeutic apheresis guidelines – 8th edition – overview with focus on hematology/oncology indications
Nancy M. Dunbar
Hematol Transfus Cell Ther. 2020;42 Supl 1:12
Open access
Essential molecular characterization of AML patients
Mehmet Yilmaz
Hematol Transfus Cell Ther. 2020;42 Supl 1:12-3
Open access
Novel approaches to the treatment of polycythemia vera
Martin H. Ellis
Hematol Transfus Cell Ther. 2020;42 Supl 1:13-4
Open access
New drugs for low grade lymphoproliferative diseases
Argiris Symeonidis
Hematol Transfus Cell Ther. 2020;42 Supl 1:14-5
Open access
Which aggressive B cell lymphoma should not be treated with RCHOP?
Christian Gisselbrecht
Hematol Transfus Cell Ther. 2020;42 Supl 1:15
Open access
How can we estimate early relapsed follicular lymphoma and how can we treat?
Ozan Salim
Hematol Transfus Cell Ther. 2020;42 Supl 1:15
Open access
Exosomes in heme malignancies and pre-cancerous states
Rajko Kusec
Hematol Transfus Cell Ther. 2020;42 Supl 1:16
Open access
Oral presentations
Isolated myeloid sarcoma causing obstructive jaundice in duodenal ampulla: a very rare case
Ömer Ekinci, Mustafa Merter, Mehmet Aslan, İlknur Calık
Hematol Transfus Cell Ther. 2020;42 Supl 1:17
Open access
Blinatumomab therapy in a relapsed acute lymphoblastic leukemia with isolated radius involvement following allogeneic bone marrow transplant: a case report
İbrahim Halil Açar, Yasa Gul Mutlu, Huseyin Derya Dincyurek, Birol Guvenç
Hematol Transfus Cell Ther. 2020;42 Supl 1:18
Open access
Cardiovascular risk reduction in chronic myeloid leukemia patients treated with the tyrosine kinase inhibitors
N. Lopina, I. Dmytrenko, D. Lopin, D. Hamov, I. Dyagil
Hematol Transfus Cell Ther. 2020;42 Supl 1:18-9
Open access
Analysis of demographic and clinical characteristics of primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis patients
P. Akyol, A. Yıldız, M. Albayrak, H. Afacan Öztürk, S. Maral, M. Reis Aras, F. YıLmaz, B. Saglam, M. Tıglıoglu, U. Malkan
Hematol Transfus Cell Ther. 2020;42 Supl 1:19
Open access
Incidence in PH-negative myeloproliferative neoplasms in armenia from 2005 to 2019
L. Sahakyan, A. Ter-Grigoryan, M. Badikyan, Y. Hakobyan, A. Saharyan, A. Shaljyan, S. Danelyan
Hematol Transfus Cell Ther. 2020;42 Supl 1:19-20
Open access
The importance of next generation sequence in patients with diffuse large B cell lymphoma
A. Bolaman, I. Yavasoglu, I. Erdogdu, A. Ozcalimli
Hematol Transfus Cell Ther. 2020;42 Supl 1:20
Open access
Real experience of brentuximab vedotin for cutaneous T cell lymphomas
F. Keklik Karadag, A. Arslan, T. Pashayev, N. Akad Soyer, F. Sahin, F. Vural, M. TöBü, G. Saydam
Hematol Transfus Cell Ther. 2020;42 Supl 1:20-1
Open access
The prognostic impact of comorbidity, nutritional and performance status on patients with diffuse large B cell lymphoma
B. Saglam, M. Albayrak, A. Yıldız, P. Akyol, M. Tiglioglu, M. Aras, F. YıLmaz, S. Maral, H. Ozturk
Hematol Transfus Cell Ther. 2020;42 Supl 1:21
Open access
Can sarcopenia be a risk factor for bleomycin toxicity?
M. Koyuncu
Hematol Transfus Cell Ther. 2020;42 Supl 1:21-2
Open access
Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: old/new in novel agents’ era
C. Cerchione, L. Catalano, D. Nappi, S. Rocco, S. Palmieri, A. Pareto, F. Pane, F. Ferrara, G. Martinelli
Hematol Transfus Cell Ther. 2020;42 Supl 1:22
Open access
Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study
E. Terpos, A. Symeonidis, S. Delimpasi, E. Zamagni, E. Katodritou, E. Rivolti, M. Kyrtsonis, D. Fotiou, N. Kanellias, M. Migkou, M. Roussou, M. Gavriatopoulou, E. Hatjiharissi, M. Cavo, M. Dimopoulos
Hematol Transfus Cell Ther. 2020;42 Supl 1:22-3
Open access
A novel microrna signature with clinical significance in multiple myeloma
A. Papanota, P. Artemaki, P. Karousi, C. Liacos, M. Gavriatopoulou, E. Kastritis, C. Kontos, M. Dimopoulos, A. Scorilas, E. Terpos
Hematol Transfus Cell Ther. 2020;42 Supl 1:23-4
Open access
Peripheral blood immune profiling of multiple myeloma patients at diagnosis: correlations with circulating plasma cells
K. Papadimitriou, I. Ntanasis-Stathopoulos, N. Tsakirakis, M. Gavriatopoulou, I. Kostopoulos, E. Kastritis, N. Orologas-Stavrou, M. Dimopoulos, O. Tsitsilonis, E. Terpos
Hematol Transfus Cell Ther. 2020;42 Supl 1:24
Open access
The factors that affect the results of the response to rituximab treatment in ITP patients
O. Beyler, A. Gunes, G. Korkmaz Akat, F. Ceran, S. Dagdas, G. Ozet
Hematol Transfus Cell Ther. 2020;42 Supl 1:25
Open access
The role of T helper 22 cells during engraftment at hematopoietic stem cell transplantation
O. Yucel, M. Ulubahsi, T. Ulas, O. Salim, D. Ekinci, L. Undar
Hematol Transfus Cell Ther. 2020;42 Supl 1:26
Open access
Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemia
E. Aladag, H. Goker, H. Demiroglu, S. Aksu, N. Sayınalp, I. Haznedaroglu, O. Ozcebe, Y. Buyukasık
Hematol Transfus Cell Ther. 2020;42 Supl 1:27
Open access
Hematological parameters and peripheral blood morphologic abnormalities in children with COVID-19
N. Yarali, Y. Akcabelen, Y. Unal, A. Ozkaya-Parlakay
Hematol Transfus Cell Ther. 2020;42 Supl 1:27
Open access
Risk factors and outcomes related to intensive care unit admission of children with hematological and solid organ malignancies: single-center experience
C. Kaya, Z. Guzelkucuk, D. Ozyoruk, N. Ozbek, N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:28
Open access
A case report of RAS-associated autoimmune lymphoproliferative disorder
C. Coskun, F. Gumruk, M. Cemaloglu, M. Orhan, I. Tezcan, S. Unal
Hematol Transfus Cell Ther. 2020;42 Supl 1:28-9
Open access
Bone mineral density and bone resorption in the acute leukemia during childhood
S. Akarsu, S. Gozdasoglu
Hematol Transfus Cell Ther. 2020;42 Supl 1:29
Open access
A girl with SAMD9L mutation presenting with pancytopenia, immunodeficiency and myelodsyplasia
D. Gurlek Gokcebay, I. Yaman Bajin, Y. Akcabelen, A. Koca Yozgat, O. Arman Bilir, I. Ok Bozkaya, N. Yarali, N. Ozbek
Hematol Transfus Cell Ther. 2020;42 Supl 1:29-30
Open access
The effects of vitamin D deficiency on myocardial deformation and functions in patients with β-thalassemia
A. Koca Yozgat, E. Azak, D. Kaçar, M. Işık, O. Arman Bilir, I. Çetin, N. Ozbek, N. Yaralı
Hematol Transfus Cell Ther. 2020;42 Supl 1:30
Open access
The molecular spectrum of patients with hereditary spherocytosis: a single center experience
C. Coskun, S. Unal, F. Gumruk
Hematol Transfus Cell Ther. 2020;42 Supl 1:30-1
Open access
Eltrombopag for thrombocytopenia following pediatric allogeneic hematopoietic stem cell transplantation
A. Akyay, Y. Oncul
Hematol Transfus Cell Ther. 2020;42 Supl 1:31
Open access
Bone marrow involvement in non-small cell lung cancer
S. Chulkova, N. Tupitsyn
Hematol Transfus Cell Ther. 2020;42 Supl 1:32
Open access
The prognostic significance of neutrophil/lymphocyte ratio in patients with terminal cancer
M. Alemdar, S. Sezgin Goksu, A. Tatli, H. Coskun
Hematol Transfus Cell Ther. 2020;42 Supl 1:32-3
Open access
Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian cancer: a rare case report
Y. Ilhan, M. Korkmaz, E. Taskiran Guzel, K. Mammadova, S. Sezgin Goksu, A. Tatlı, H. Coskun
Hematol Transfus Cell Ther. 2020;42 Supl 1:33
Open access
Gastroenteropancreatic neuroendocrine carcinoma: single center experience
A. Sakin, O. Can
Hematol Transfus Cell Ther. 2020;42 Supl 1:33-4
Open access
Poster presentations
Hypercalcemia due to the interaction between all trans retinoic acid and posaconazole used for acute promyelocytic leukemia treatment
H. Afacan Öztürk, M. Albayrak, S. Maral, M. Reis Aras, F. YıLmaz, P. Akyol, M. Tiglioglu
Hematol Transfus Cell Ther. 2020;42 Supl 1:35
Open access
Acute cerebellar syndrome after high dose cytosine arabinoside treatment: case report
F. Yilmaz, M. Tiglioglu, P. Akyol, M. Reis Aras, B. SagLam, S. Maral, U. Malkan, M. Albayrak
Hematol Transfus Cell Ther. 2020;42 Supl 1:36
Open access
An unusual case report: myeloid sarcoma presented with appendicitis
F. Yilmaz, M. Albayrak, P. Akyol, B. Saglam, M. Tiglioglu, M. Reis Ara, H. Afacan Özturk
Hematol Transfus Cell Ther. 2020;42 Supl 1:36-7
Open access
Postdural puncture superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia
A. Ozturkmen, E. Gulturk, o. Yildiz, F. Hindilerden
Hematol Transfus Cell Ther. 2020;42 Supl 1:37
Open access
Retrospective analysis of all patients single center experience
E. Kelkitli, E. Arslan, M. Turgut
Hematol Transfus Cell Ther. 2020;42 Supl 1:37-8
Open access
Case report: acute lymphoblastic leukemia with bone involvement
F. Yavaşoglu, C. Özdemir
Hematol Transfus Cell Ther. 2020;42 Supl 1:38
Open access
Chronic lymphocytic leukemia presenting as pulmonary involvement in an elderly patient: a case report
O. Ekinci, A. Dogan, M. Aslan, I. Aras, C. Demir
Hematol Transfus Cell Ther. 2020;42 Supl 1:38-9
Open access
Frequency of brucellosis and hepatitis b virus seropositivity in patients with chronic lymphocytic leukemia
O. Ekinci, S. Ebinc, A. Dogan, C. Demir
Hematol Transfus Cell Ther. 2020;42 Supl 1:39
Open access
Epidemiological spectrum and diagnosis patterns of hematological malignancies in the republic of moldova
V. Musteata, L. Catrinici, V. Stratan, L. Musteata
Hematol Transfus Cell Ther. 2020;42 Supl 1:39-40
Open access
A rare case: coexistence of small cell lung cancer and chronic lymphocytic leukemia
M. Tıglıoglu, B. Saglam, M. Reis Aras, F. Yılmaz, U. Malkan, H. Afacan Ozturk, P. Akyol, M. Albayrak
Hematol Transfus Cell Ther. 2020;42 Supl 1:40
Open access
Stevens–Johnson syndrome secondary to rituximab administration in a chronic lymphocytic leukemia patient
V. Tomacinschii, M. Robu, S. Buruiana, V. Musteata
Hematol Transfus Cell Ther. 2020;42 Supl 1:40-1
Open access
Concomitant essential thrombocythemia and mature B-lymphoproliferative disorder in a patient
A. Butt, R. Qudus, N. Ali
Hematol Transfus Cell Ther. 2020;42 Supl 1:41-2
Open access
Acute phase reactants in chronic inflammation leading to secondary myelofibrosis in polycythemia vera and essential thrombocytosis
E. Aladag, I. Haznedaroglu, N. Sayinalp, H. Demiroglu, H. Goker, S. Aksu, O. Ozcebe, A. Ayhan, Y. Buyukasik
Hematol Transfus Cell Ther. 2020;42 Supl 1:42
Open access
Polycythemia vera: updates in diagnosis and treatment outcomes
L. Musteata, S. Pinzari, V. Musteata, N. Sghibneva-Bobeico, A. Dorogan
Hematol Transfus Cell Ther. 2020;42 Supl 1:42-3
Open access
Disease and clinical characteristics of patients with chronic myeloproliferative neoplasms: 11-year single center experience
P. Akyol, A. Yıldız, H. Afacan Öztürk, S. Maral, M. Reis Aras, F. Yılmaz, B. Saglam, M. Tıglıoglu, M. Albayrak
Hematol Transfus Cell Ther. 2020;42 Supl 1:43
Open access
The frequency of calreticulin and mpl gene mutations in bcr-abl and jak2 unmutated chronic myeloproliferative neoplasms and its effect on the outcome
T. Tiryaki, A. DağLar Aday, M. Güzel Mastanzade, M. ÖZbalak, D. Özlük, F.Y. Onal Hindilerden, M. Yenerel, A. Yavuz, S. Kalayoğlu Beşışık, M. Nalçacı
Hematol Transfus Cell Ther. 2020;42 Supl 1:43
Open access
Study of JAK2V617F gene allele burden in polycythemia vera
F. Khalilova, A. Kerimov, A. Hasanova, A. Aghayev
Hematol Transfus Cell Ther. 2020;42 Supl 1:44
Open access
Clinical and anamnestic signs of hypercoagulation in patients with β-thalassemia
N. Alieva, P. Safarova, A. Kerimov
Hematol Transfus Cell Ther. 2020;42 Supl 1:44-5
Open access
Factor XIII deficiency case with posttravmatic subcutaneous bleeding
M. Reis Aras, M. Tıglıoğou, B. Sağlam, P. Akyol, Ü. Malkan, A. Alan, M. Albayrak
Hematol Transfus Cell Ther. 2020;42 Supl 1:45
Open access
Acute ischemic stroke presentation of otherwise asymptomatic covid-19 patient
E. Aksoy, Y. Tor, S. Kalayoglu Besisik, A. Alibeyoglu, M. Kose, N. Senkal, A. Cagatay, M. Erelel, T. Tukek
Hematol Transfus Cell Ther. 2020;42 Supl 1:46
Open access
Isolated primary spinal mucosa-associated lymphoid tissue (malt) lymphoma: a rare case report
O. Ekinci, A. Dogan, M. Aslan, I. Aras, C. Demir
Hematol Transfus Cell Ther. 2020;42 Supl 1:46-7
Open access
Ir2 leading to complete remission in r/r richter syndrome – a case report
Emin Abdullayev, Christoph Buhl, Judith Niederland, Herrad Baurmann, Bertram Glass
Hematol Transfus Cell Ther. 2020;42 Supl 1:47
Open access
Primary spinal extramedullary diffuse large B-cell lymphoma presenting with initial spinal cord compression: a case report
O. Ekinci, A. Dogan, M. Aslan, I. Aras, C. Demir
Hematol Transfus Cell Ther. 2020;42 Supl 1:47-8
Open access
Comparison of 68ga-psma and 18f-fdg pet/ct uptake in different lymphoma
S. Souza, M. Delamain, N. Tobar, V. Castro, F. Frasson, B. Amorim, E. Etchebehere, K. Mariana, J. Mengatti, E.B. Araujo, E. Perini, C. De Souza, A. Santos, I. Lorant-Metze, C. Ramos
Hematol Transfus Cell Ther. 2020;42 Supl 1:48
Open access
Prognostic value of pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratio in diffuse large B-cell lymphoma: a single-center experience
G. Dagci, M. Guzel Mastanzade, M. Ozbalak, D. Ozluk, T. Tiryaki, I. Yonal Hindilerden, M. Yenerel, M. Nalcaci, S. Kalayoglu Besisik
Hematol Transfus Cell Ther. 2020;42 Supl 1:48-9
Open access
Two diseases in a single lymph node: nodular lymphocyte predominant hodgkin lymphoma and kaposi's sarcoma
E. Turan Erkek, S. Yazıcı, S. Mazmanoglu, N. Özdemir Barışık
Hematol Transfus Cell Ther. 2020;42 Supl 1:49-50
Open access
Extranodal marginal zone lymphoma of the ocular adnexa
A. Gül, O. Aydın, E. Kelkitli, H. Atay, M. Turgut
Hematol Transfus Cell Ther. 2020;42 Supl 1:50
Open access
Alk (−) anaplastic large cell lymphoma diagnosed by tongue root biopsy: case report
F. Yilmaz, M. Albayrak, M. Tiglioglu, M. Aras, S. Maral, A. Yildiz, U. Malkan
Hematol Transfus Cell Ther. 2020;42 Supl 1:50
Open access
Polatuzumab based chemoimmunotherapy showing complete response in a patient of r/r diffuse large b-cell lymphoma
U. Atas, E. Vural, U. Iltar, O. Yucel, O. Salim, L. Undar
Hematol Transfus Cell Ther. 2020;42 Supl 1:51
Open access
Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study
M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin
Hematol Transfus Cell Ther. 2020;42 Supl 1:51-2
Open access
Relapse of multiple myeloma presenting as extramedullary plasmacytoma surrounding the aorta: a rare case report
O. Ekinci, A. Dogan, M. Aslan, S. Ebinc, C. Demir
Hematol Transfus Cell Ther. 2020;42 Supl 1:52
Open access
A rare subtype of poems syndrome: IGG4 subtype
F. Hindilerden, I. Yonal, D. Sakiz
Hematol Transfus Cell Ther. 2020;42 Supl 1:53
Open access
Monoclonal gammopathy of undertemined significance and solitary plasmacytoma: progression factors in population of gomel region in belarus
Z. Kozich, V. Martinkov, D. Zinovkin, Z. Pugacheva, M. Zhandarov, L. Smirnova
Hematol Transfus Cell Ther. 2020;42 Supl 1:53-4
Open access
Poems syndrome: a “multifaceted” entity of plasma cell disorder
D. Sevoyan, D. Hakobyan, D. Meliksetyan, D. Ter-Grigoryan, D. Ghazaryan, D. Grigoryan, D. Martirosyan
Hematol Transfus Cell Ther. 2020;42 Supl 1:54
Open access
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
C. Cerchione, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, A. Pareto, F. Pane, G. Martinelli
Hematol Transfus Cell Ther. 2020;42 Supl 1:55
Open access
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
C. Cerchione, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, F. Pane, G. Martinelli
Hematol Transfus Cell Ther. 2020;42 Supl 1:55-6
Open access
The relationship of hepcidin, soluble transferrine receptor, growth differentiation factor-15 and anemia in multiple myeloma
B. Onec, D. Köş, G. Altun, M. Sungur
Hematol Transfus Cell Ther. 2020;42 Supl 1:56
Open access
Serum & salivary ferritin levels in iron deficiency anemia is there is a difference?
A. Gawaly, G. Alghazaly
Hematol Transfus Cell Ther. 2020;42 Supl 1:56
Open access
Hepcidin level changes in type 2 diabetes
A. Gawaly, F. Atyia
Hematol Transfus Cell Ther. 2020;42 Supl 1:57
Open access
Chemotherapy delivering port-a-cath migration into the heart: a case report
A. Omar, O. Bheleel, A. Abushaala, L. Sabei, A. Rakha
Hematol Transfus Cell Ther. 2020;42 Supl 1:57
Open access
Reactive lymphocytes in blood film of a covid-19 iraqi patient: a case report
A. Al-Ani
Hematol Transfus Cell Ther. 2020;42 Supl 1:57-8
Open access
A study of hematological disease prevalence in covid-19 pandemic: a single center experience
V. Gursoy
Hematol Transfus Cell Ther. 2020;42 Supl 1:58
Open access
A case of malignant peritoneal mesothelioma as a rare cause of autoimmune haemolytic anaemia
I. Whybrow Huppatz, V. Singh
Hematol Transfus Cell Ther. 2020;42 Supl 1:58-9
Open access
Erdheim–Chester disease: a single center experience
E. Turan Erkek, N. Demir, S. Erdem, G. Ozkan, O. Arslan, S. Kalayoglu BesıSıK
Hematol Transfus Cell Ther. 2020;42 Supl 1:59-60
Open access
Acute brucellosis presenting as leukocytoclastic vasculitis
O. Ekinci, S. Ebinc, A. Dogan, M. Aslan, C. Demir
Hematol Transfus Cell Ther. 2020;42 Supl 1:60
Open access
The frequency of anemia in the elderly patient population in Van Province, Turkey. A cross-sectional study
O. Ekinci, E. Eker
Hematol Transfus Cell Ther. 2020;42 Supl 1:60-1
Open access
Effect of helicobacter pylori infection on the first-line treatment outcomes in patients with immune thrombocytopenic purpura
O. Ekinci, S. Ebinc, M. Aslan, A. Dogan, C. Demir
Hematol Transfus Cell Ther. 2020;42 Supl 1:61
Open access
Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study
S. Besisik, J. De La Rubia, F. Peyvandi, M. Scully, S. Cataland, P. Coppo, J. A. Kremer Hovinga, P. Knoebl, A. Metjian, K. Pavenski, H. De Winter, R. De Passos Sousa, F. Callewaert
Hematol Transfus Cell Ther. 2020;42 Supl 1:62
Open access
Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
L. Kaynar, P. Coppo, M. Scully, J. De La Rubia, F. Peyvandi, S. Cataland, J. A. Kremer Hovinga, P. Knoebl, K. Pavenski, J. Minkue Mi Edou, F. Callewaert, R. De Passos Sousa
Hematol Transfus Cell Ther. 2020;42 Supl 1:62-3
Open access
Transplant in aplastic anemia using combined G-CSF primed blood and bone marrow stem cells – a retrospective analysis
N. Ali, A. Butt, B. Altaf, S. Adil, U. Shaikh
Hematol Transfus Cell Ther. 2020;42 Supl 1:63
Open access
Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
U. Malkan, H. Demiroglu, Y. Buyukasik, A. Karatas, E. Aladag, H. Goker
Hematol Transfus Cell Ther. 2020;42 Supl 1:64
Open access
Are the hemoglobin values different after sex-mismatched allogeneic stem cell transplantation?
S. Izmir Guner, M. Yanmaz
Hematol Transfus Cell Ther. 2020;42 Supl 1:64-5
Open access
Experience of istanbul faculty of medicine bone marrow bank: periodical activity documentation
F. Oguz, A. Erol, M. Suleymanoglu, C. Cinar, H. Senturk Ciftci, S. Kalayoglu Besisik
Hematol Transfus Cell Ther. 2020;42 Supl 1:65
Open access
Therapeutic plasma exchange in gastric signet ring cell carcinoma presenting as microangiopathic hemolytic anemia: a rare case report
O. Ekinci, M. Merter, M. Aslan, I. Aras
Hematol Transfus Cell Ther. 2020;42 Supl 1:65-6
Open access
A signet ring cell carcinoma presented as refractory acquired thrombotic thrombocytopenic purpura
U. Malkan, M. Albayrak, H. Ozturk, M. Reis Aras, B. Saglam, K. Dogan
Hematol Transfus Cell Ther. 2020;42 Supl 1:66
Open access
Health-related quality of life for children with leukemia: child and parental perceptions
E. Ocak, A. Koca Yozgat, D. Kaçar, I. Ayrancı Sucaklı, N. Ozbek, O. Şükran Üneri, H. Yaralı
Hematol Transfus Cell Ther. 2020;42 Supl 1:67
Open access
Rare infectious agents in children with hematological disease
Y. Akcabelen, A. Koca Yozgat, Z. Guzelkucuk, O. Arman Bilir, M. Isik, D. Kacar, D. Gurlek Gokcebay, N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:67-8
Open access
Idiopathic hypereosinophilic syndrome associated pulmonary hypertension in a child
Y. Akcabelen, T. Bayhan, G. Cinel, I. Ece, N. Ozbek
Hematol Transfus Cell Ther. 2020;42 Supl 1:68
Open access
A rare variant of dyskeratosis congenita: RTEL1 defect
C. Coskun, S. Unal, N. Akarsu
Hematol Transfus Cell Ther. 2020;42 Supl 1:68-9
Open access
Acquired aplastic anemia in childhood: single-center experience
M. Bilici, R. Tuna, S. Sahin, Z. Karakas, A. Unuvar, S. Anak, D. Tugcu, S. Karaman
Hematol Transfus Cell Ther. 2020;42 Supl 1:69
Open access
The course of intracranial bleeding in the patient with immune thrombocytopenia
M. Babayev, A. Ahmadova, K. Mehtiyeva, N. Babayeva
Hematol Transfus Cell Ther. 2020;42 Supl 1:69-70
Open access
The cause of very severe trombocytosis: iron deficiency anemia
V. Uzel, S. SavaŞ, M. Soker
Hematol Transfus Cell Ther. 2020;42 Supl 1:70
Open access
Immune markers are closely related to the remission achievement in childhood acute myeloid leukemia
A. Palladina, N. Kupryshina, N. Tupitsyn, A. Popa
Hematol Transfus Cell Ther. 2020;42 Supl 1:70-1
Open access
The course of toxic hepatitis at the stage of treatment consolidation acute leukemia in children
M. Babayev, A. Ahmadova, K. Mehtiyeva, N. Babayeva
Hematol Transfus Cell Ther. 2020;42 Supl 1:71
Open access
Klippel–Trenaunay syndrome associated with chronic myeloid leukemia
C. Coskun, T. Aksu, F. Gumruk, S. Unal
Hematol Transfus Cell Ther. 2020;42 Supl 1:71
Open access
Multiple relapsed acute lymphoblastic leukemia with t(9;13) in a child
D. Gurlek Gokcebay, Y. Akcabelen, A. Koca Yozgat, D. Kacar, O. Arman Bilir, M. Isik, I. Ok Bozkaya, N. Ozbek, N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:72
Open access
Occurence of acute myeloid leukemia after primary hepatic carcinoma in a patient who had liver transplantation
C. Coskun, S. Unal, A. Uner, T. Aksu, S. Aytac, B. Kuskonmaz, F. Gumruk
Hematol Transfus Cell Ther. 2020;42 Supl 1:72-3
Open access
Acute lymphoblastic leukemia with ebv infection and multiple chromosomal abnormalities in a child
D. Kacar, A. Koca Yozgat, S. Sahin, Y. Akcabelen, F. Kurtipek, D. Gurlek Gokcebay, N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:73
Open access
Hypercalcemia due to concomitant use of all trans retinoic acid and voriconazole
A. Koca Yozgat, Y. Akçabelen, Y. Unal, N. Yaralı
Hematol Transfus Cell Ther. 2020;42 Supl 1:73
Open access
Acute lymphoblastic leukemia in the context of constitutional mismatch repair deficiency syndrome: a case report
D. Kacar, A. Koca Yozgat, S. Sahin, Y. Akcabelen, F. Kurtipek, D. Gurlek Gokcebay, N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:74
Open access
Hematologic manifestations associated with deficiency of adenosine deaminase 2 and a novel ada2 variant
E. Hanafy, M. Al Twaijri, N. Al Bolowi
Hematol Transfus Cell Ther. 2020;42 Supl 1:75
Open access
Pyruvate kinase deficiency misdiagnosed as congenital dyserythropoietic anemia type i
A. Koca Yozgat, A. Yazal Erdem, D. Kaçar, N. Özbek, N. Yaralı
Hematol Transfus Cell Ther. 2020;42 Supl 1:75-6
Open access
How to treat and manage covid19 in SCD patients
N. Verdiyeva, T. Ibrahimova, A. Nasibova, V. Huseynov
Hematol Transfus Cell Ther. 2020;42 Supl 1:76
Open access
High-dose methyl prednisolone in veno-occlusive disease
A. Akyay, Y. Oncul
Hematol Transfus Cell Ther. 2020;42 Supl 1:76
Open access
Isolated extramedullary relapse after hematopoietic stem cell transplantation
Z. Guzelkucuk, P. Isık, O. Arman Bilir, D. Kacar, A. Koca Yozgat, M. Isık, D. Gurlek Gokcebay, I. Ok Bozkaya, N. Ozbek, N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:77
Open access
Candida guillermondii onychomycosis involving fingernails in a breast cancer patient under decetaxel chemothrapy
Y. Merad, H. Derrar, M. Belkacemi
Hematol Transfus Cell Ther. 2020;42 Supl 1:77
Open access
Systemic inflammatory markers as predictors of response to chemoradiotherapy in rectal cancer
S. Seber, A. Yolcu
Hematol Transfus Cell Ther. 2020;42 Supl 1:78
Open access
Idiomas
Hematology, Transfusion and Cell Therapy

Subscribe to our newsletter